Challenges  ||| S:0 E:11 ||| NNS
in  ||| S:11 E:14 ||| IN
multiple  ||| S:14 E:23 ||| JJ
sclerosis ||| S:23 E:32 ||| NN
;  ||| S:32 E:34 ||| :
how  ||| S:34 E:38 ||| WRB
to  ||| S:38 E:41 ||| TO
define  ||| S:41 E:48 ||| VB
occurence  ||| S:48 E:58 ||| VBN
of  ||| S:58 E:61 ||| IN
progression  ||| S:61 E:73 ||| VBG
The  ||| S:73 E:77 ||| DT
challenges  ||| S:77 E:88 ||| NNS
in  ||| S:88 E:91 ||| IN
MS  ||| S:91 E:94 ||| NNP
are  ||| S:94 E:98 ||| VBP
related  ||| S:98 E:106 ||| VBN
to  ||| S:106 E:109 ||| TO
number  ||| S:109 E:116 ||| NN
of  ||| S:116 E:119 ||| IN
controversies  ||| S:119 E:133 ||| NNS
in  ||| S:133 E:136 ||| IN
various  ||| S:136 E:144 ||| JJ
aspects  ||| S:144 E:152 ||| NNS
of  ||| S:152 E:155 ||| IN
disease  ||| S:155 E:163 ||| NN
but  ||| S:163 E:167 ||| CC
the  ||| S:167 E:171 ||| DT
relationship  ||| S:171 E:184 ||| NN
between  ||| S:184 E:192 ||| IN
relapses  ||| S:192 E:201 ||| NN
and  ||| S:201 E:205 ||| CC
disability  ||| S:205 E:216 ||| JJ
progression ||| S:216 E:227 ||| NN
,  ||| S:227 E:229 ||| ,
or  ||| S:229 E:232 ||| CC
aspects  ||| S:232 E:240 ||| NNS
of  ||| S:240 E:243 ||| IN
MS  ||| S:243 E:246 ||| NNP
as  ||| S:246 E:249 ||| IN
an  ||| S:249 E:252 ||| DT
inflammatory  ||| S:252 E:265 ||| JJ
and ||| S:265 E:268 ||| CC
/ ||| S:268 E:269 ||| NNP
or  ||| S:269 E:272 ||| CC
neurodegenerative  ||| S:272 E:290 ||| JJ
disease  ||| S:290 E:298 ||| NN
are  ||| S:298 E:302 ||| VBP
extremely  ||| S:302 E:312 ||| RB
important  ||| S:312 E:322 ||| JJ
because  ||| S:322 E:330 ||| IN
of  ||| S:330 E:333 ||| IN
its  ||| S:333 E:337 ||| PRP$
implications  ||| S:337 E:350 ||| NNS
on  ||| S:350 E:353 ||| IN
prognosis  ||| S:353 E:363 ||| NN
and  ||| S:363 E:367 ||| CC
therapy  ||| S:367 E:375 ||| NN
of  ||| S:375 E:378 ||| IN
MS ||| S:378 E:380 ||| NNP
.  ||| S:380 E:382 ||| .
MS  ||| S:382 E:385 ||| NNP
was  ||| S:385 E:389 ||| VBD
classically  ||| S:389 E:401 ||| VBN
regarded  ||| S:401 E:410 ||| VBN
as  ||| S:410 E:413 ||| IN
white  ||| S:413 E:419 ||| JJ
matter  ||| S:419 E:426 ||| NN
inflammatory  ||| S:426 E:439 ||| JJ
disease ||| S:439 E:446 ||| NN
,  ||| S:446 E:448 ||| ,
while  ||| S:448 E:454 ||| IN
disability  ||| S:454 E:465 ||| JJ
progression ||| S:465 E:476 ||| NN
,  ||| S:476 E:478 ||| ,
brain  ||| S:478 E:484 ||| NN
and  ||| S:484 E:488 ||| CC
spinal  ||| S:488 E:495 ||| JJ
cord  ||| S:495 E:500 ||| NN
atrophy  ||| S:500 E:508 ||| NNS
were  ||| S:508 E:513 ||| VBD
regarded  ||| S:513 E:522 ||| VBN
as  ||| S:522 E:525 ||| IN
a  ||| S:525 E:527 ||| DT
consequence  ||| S:527 E:539 ||| NN
of  ||| S:539 E:542 ||| IN
global  ||| S:542 E:549 ||| JJ
inflammation  ||| S:549 E:562 ||| NN
of  ||| S:562 E:565 ||| IN
NAWM  ||| S:565 E:570 ||| NNP
and  ||| S:570 E:574 ||| CC
secondary  ||| S:574 E:584 ||| JJ
involvement  ||| S:584 E:596 ||| NN
of  ||| S:596 E:599 ||| IN
grey  ||| S:599 E:604 ||| JJ
matter ||| S:604 E:610 ||| NN
.  ||| S:610 E:612 ||| .
More  ||| S:612 E:617 ||| RBR
recent  ||| S:617 E:624 ||| JJ
histopathology  ||| S:624 E:639 ||| JJ
studies ||| S:639 E:646 ||| NNS
,  ||| S:646 E:648 ||| ,
but  ||| S:648 E:652 ||| CC
also  ||| S:652 E:657 ||| RB
new ||| S:657 E:660 ||| JJ
,  ||| S:660 E:662 ||| ,
modern  ||| S:662 E:669 ||| JJ
MRI  ||| S:669 E:673 ||| NNP
techniques  ||| S:673 E:684 ||| NNS
changed  ||| S:684 E:692 ||| VBD
this  ||| S:692 E:697 ||| DT
view  ||| S:697 E:702 ||| NN
in  ||| S:702 E:705 ||| IN
MS  ||| S:705 E:708 ||| NNP
as  ||| S:708 E:711 ||| IN
a  ||| S:711 E:713 ||| DT
prominent  ||| S:713 E:723 ||| JJ
grey  ||| S:723 E:728 ||| NN
and  ||| S:728 E:732 ||| CC
white  ||| S:732 E:738 ||| JJ
matter  ||| S:738 E:745 ||| NN
disease ||| S:745 E:752 ||| NN
.  ||| S:752 E:754 ||| .
Inflammatory  ||| S:754 E:767 ||| JJ
demyelination  ||| S:767 E:781 ||| NN
of  ||| S:781 E:784 ||| IN
grey  ||| S:784 E:789 ||| JJ
matter  ||| S:789 E:796 ||| NN
occurs  ||| S:796 E:803 ||| VBZ
early  ||| S:803 E:809 ||| RB
in  ||| S:809 E:812 ||| IN
MS  ||| S:812 E:815 ||| NNP
sometimes  ||| S:815 E:825 ||| RB
even  ||| S:825 E:830 ||| RB
before  ||| S:830 E:837 ||| IN
occurrence  ||| S:837 E:848 ||| NN
of  ||| S:848 E:851 ||| IN
white  ||| S:851 E:857 ||| JJ
matter  ||| S:857 E:864 ||| NN
lesions ||| S:864 E:871 ||| NNS
.  ||| S:871 E:873 ||| .
Inspite  ||| S:873 E:881 ||| NNP
of  ||| S:881 E:884 ||| IN
early  ||| S:884 E:890 ||| JJ
therapy  ||| S:890 E:898 ||| NN
of  ||| S:898 E:901 ||| IN
MS  ||| S:901 E:904 ||| NNP
with  ||| S:904 E:909 ||| IN
immunomodulatory  ||| S:909 E:926 ||| JJ
drugs  ||| S:926 E:932 ||| NNS
disability  ||| S:932 E:943 ||| JJ
progression  ||| S:943 E:955 ||| NN
and  ||| S:955 E:959 ||| CC
neurodegeneration  ||| S:959 E:977 ||| NNS
are  ||| S:977 E:981 ||| VBP
still  ||| S:981 E:987 ||| RB
important  ||| S:987 E:997 ||| JJ
and  ||| S:997 E:1001 ||| CC
common  ||| S:1001 E:1008 ||| JJ
part  ||| S:1008 E:1013 ||| NN
of  ||| S:1013 E:1016 ||| IN
MS  ||| S:1016 E:1019 ||| NNP
pathogenesis ||| S:1019 E:1031 ||| NN
.  ||| S:1031 E:1033 ||| .
This  ||| S:1033 E:1038 ||| DT
indicate  ||| S:1038 E:1047 ||| NN
that  ||| S:1047 E:1052 ||| IN
treatment  ||| S:1052 E:1062 ||| NN
is  ||| S:1062 E:1065 ||| VBZ
not  ||| S:1065 E:1069 ||| RB
adequate  ||| S:1069 E:1078 ||| JJ
to  ||| S:1078 E:1081 ||| TO
the  ||| S:1081 E:1085 ||| DT
predicted  ||| S:1085 E:1095 ||| JJ
severity  ||| S:1095 E:1104 ||| NN
of  ||| S:1104 E:1107 ||| IN
MS ||| S:1107 E:1109 ||| NNP
,  ||| S:1109 E:1111 ||| ,
or  ||| S:1111 E:1114 ||| CC
perhaps  ||| S:1114 E:1122 ||| RB
to  ||| S:1122 E:1125 ||| TO
the  ||| S:1125 E:1129 ||| DT
basic  ||| S:1129 E:1135 ||| JJ
pathogenetic  ||| S:1135 E:1148 ||| JJ
mechanisms  ||| S:1148 E:1159 ||| NNS
in  ||| S:1159 E:1162 ||| IN
MS ||| S:1162 E:1164 ||| NNP
.  ||| S:1164 E:1166 ||| .
Beside  ||| S:1166 E:1173 ||| IN
acute  ||| S:1173 E:1179 ||| JJ
clinical  ||| S:1179 E:1188 ||| JJ
symptoms ||| S:1188 E:1196 ||| NNS
,  ||| S:1196 E:1198 ||| ,
conclusions  ||| S:1198 E:1210 ||| NNS
about  ||| S:1210 E:1216 ||| IN
the  ||| S:1216 E:1220 ||| DT
severity  ||| S:1220 E:1229 ||| NN
of  ||| S:1229 E:1232 ||| IN
the  ||| S:1232 E:1236 ||| DT
disease  ||| S:1236 E:1244 ||| NN
are  ||| S:1244 E:1248 ||| VBP
reflection  ||| S:1248 E:1259 ||| VBN
of  ||| S:1259 E:1262 ||| IN
MRI  ||| S:1262 E:1266 ||| NNP
sensitivity  ||| S:1266 E:1278 ||| NN
to  ||| S:1278 E:1281 ||| TO
detect  ||| S:1281 E:1288 ||| VB
focal  ||| S:1288 E:1294 ||| JJ
WM  ||| S:1294 E:1297 ||| NN
lesions  ||| S:1297 E:1305 ||| NNS
and  ||| S:1305 E:1309 ||| CC
insensitivity  ||| S:1309 E:1323 ||| JJ
to  ||| S:1323 E:1326 ||| TO
detect  ||| S:1326 E:1333 ||| VB
grey  ||| S:1333 E:1338 ||| JJ
matter  ||| S:1338 E:1345 ||| NN
lesions  ||| S:1345 E:1353 ||| NNS
which  ||| S:1353 E:1359 ||| WDT
correlate  ||| S:1359 E:1369 ||| VBZ
better  ||| S:1369 E:1376 ||| JJR
with  ||| S:1376 E:1381 ||| IN
clinical  ||| S:1381 E:1390 ||| JJ
symptoms ||| S:1390 E:1398 ||| NNS
.  ||| S:1398 E:1400 ||| .
All  ||| S:1400 E:1404 ||| DT
presented  ||| S:1404 E:1414 ||| JJ
studies  ||| S:1414 E:1422 ||| NNS
and  ||| S:1422 E:1426 ||| CC
evaluations  ||| S:1426 E:1438 ||| JJ
point  ||| S:1438 E:1444 ||| NN
to  ||| S:1444 E:1447 ||| TO
the  ||| S:1447 E:1451 ||| DT
necessity  ||| S:1451 E:1461 ||| NN
of  ||| S:1461 E:1464 ||| IN
changing  ||| S:1464 E:1473 ||| VBG
the  ||| S:1473 E:1477 ||| DT
established  ||| S:1477 E:1489 ||| JJ
diagnostic  ||| S:1489 E:1500 ||| JJ
evaluation  ||| S:1500 E:1511 ||| NN
and  ||| S:1511 E:1515 ||| CC
treatment  ||| S:1515 E:1525 ||| NN
in  ||| S:1525 E:1528 ||| IN
MS ||| S:1528 E:1530 ||| NNP
.  ||| S:1530 E:1532 ||| .
At  ||| S:1532 E:1535 ||| IN
the  ||| S:1535 E:1539 ||| DT
earliest  ||| S:1539 E:1548 ||| JJS
stage  ||| S:1548 E:1554 ||| NN
of  ||| S:1554 E:1557 ||| IN
MS  ||| S:1557 E:1560 ||| NNP
as  ||| S:1560 E:1563 ||| IN
well  ||| S:1563 E:1568 ||| RB
as  ||| S:1568 E:1571 ||| RB
in  ||| S:1571 E:1574 ||| RB
follow  ||| S:1574 E:1581 ||| VB
up  ||| S:1581 E:1584 ||| RP
of  ||| S:1584 E:1587 ||| IN
disease  ||| S:1587 E:1595 ||| NN
it  ||| S:1595 E:1598 ||| PRP
would  ||| S:1598 E:1604 ||| MD
be  ||| S:1604 E:1607 ||| VB
necessary  ||| S:1607 E:1617 ||| JJ
to  ||| S:1617 E:1620 ||| TO
apply  ||| S:1620 E:1626 ||| VB
a  ||| S:1626 E:1628 ||| DT
new  ||| S:1628 E:1632 ||| JJ
MRI  ||| S:1632 E:1636 ||| NNP
techniques  ||| S:1636 E:1647 ||| NNS
more  ||| S:1647 E:1652 ||| RBR
available  ||| S:1652 E:1662 ||| JJ
for  ||| S:1662 E:1666 ||| IN
clinical  ||| S:1666 E:1675 ||| JJ
practice  ||| S:1675 E:1684 ||| NN
such  ||| S:1684 E:1689 ||| JJ
as  ||| S:1689 E:1692 ||| IN
DIR  ||| S:1692 E:1696 ||| NNP
brain  ||| S:1696 E:1702 ||| NN
MR  ||| S:1702 E:1705 ||| NNP
imaging  ||| S:1705 E:1713 ||| NN
at  ||| S:1713 E:1716 ||| IN
3T  ||| S:1716 E:1719 ||| CD
because  ||| S:1719 E:1727 ||| IN
of  ||| S:1727 E:1730 ||| IN
their  ||| S:1730 E:1736 ||| PRP$
sensitivity  ||| S:1736 E:1748 ||| NN
to  ||| S:1748 E:1751 ||| TO
detect  ||| S:1751 E:1758 ||| VB
grey  ||| S:1758 E:1763 ||| JJ
matter  ||| S:1763 E:1770 ||| NN
lesions ||| S:1770 E:1777 ||| NNS
.  ||| S:1777 E:1779 ||| .
In  ||| S:1779 E:1782 ||| IN
patient  ||| S:1782 E:1790 ||| NN
with  ||| S:1790 E:1795 ||| IN
present  ||| S:1795 E:1803 ||| JJ
cortical  ||| S:1803 E:1812 ||| NNS
lesions  ||| S:1812 E:1820 ||| VBP
even  ||| S:1820 E:1825 ||| RB
in  ||| S:1825 E:1828 ||| IN
earliest  ||| S:1828 E:1837 ||| JJS
stages  ||| S:1837 E:1844 ||| NNS
of  ||| S:1844 E:1847 ||| IN
MS  ||| S:1847 E:1850 ||| NNP
depending  ||| S:1850 E:1860 ||| VBG
on  ||| S:1860 E:1863 ||| IN
severity  ||| S:1863 E:1872 ||| NN
of  ||| S:1872 E:1875 ||| IN
grey  ||| S:1875 E:1880 ||| JJ
matter  ||| S:1880 E:1887 ||| NN
involvement  ||| S:1887 E:1899 ||| NN
more  ||| S:1899 E:1904 ||| RBR
efficacious  ||| S:1904 E:1916 ||| JJ
therapy  ||| S:1916 E:1924 ||| NN
like  ||| S:1924 E:1929 ||| IN
second  ||| S:1929 E:1936 ||| JJ
or  ||| S:1936 E:1939 ||| CC
even  ||| S:1939 E:1944 ||| RB
third  ||| S:1944 E:1950 ||| JJ
line  ||| S:1950 E:1955 ||| NN
therapy  ||| S:1955 E:1963 ||| NN
should  ||| S:1963 E:1970 ||| MD
start ||| S:1970 E:1975 ||| VB
.  ||| S:1975 E:1977 ||| .
